Pheast Therapeutics
Phase 1At Pheast Therapeutics, we are developing new innate immune checkpoint inhibitors, including anti-CD24, to unleash the power of macrophages on aggressive cancers.
Founded
2020
Focus
OncologyImmunology
About
At Pheast Therapeutics, we are developing new innate immune checkpoint inhibitors, including anti-CD24, to unleash the power of macrophages on aggressive cancers.
Funding History
1Total raised: $76M
Seed$76MAndreessen HorowitzOct 15, 2022
Company Info
TypePrivate
Founded2020
LocationPalo Alto, United States
StagePhase 1
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile